The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the best medical AI stocks to buy now. On March 31, Recursion moved to supercharge its AI-driven drug discovery platform through an expanded partnership with Citeline. Citeline is a leading provider of data, analytics, and insights to companies in the life sciences and pharmaceutical industries.

As part of the expanded partnership, Recursion will add Citeline’s real-world data capabilities to its platform. This integration is intended to improve clinical trial design and development decisions. Recursion uses artificial intelligence to reduce the time and cost of developing new medicines. It’s focused on developing treatments for cancer and rare diseases, among others.

The company doesn’t have a product on the market yet, but it has a large pipeline of potential drug products. Some are wholly owned projects, while others are partnered programs involving major drug makers such as Roche, Merck, Bayer, and Sanofi.

In February last year, Bloomberg reported that Recursion was considered an Amazon Prime-like subscription sales model for its drugs when they hit the market. Under this model, companies could pay a fixed monthly fee to access Recursion’s collection of medicines regardless of the price of each drug. This approach could ensure revenue stability for the company.

At the end of 2025, Recursion had received more than $500 million in milestone payments on its partnered programs. It estimates future potential milestone payments at more than $300 million. The company closed 2025 with $754 million of cash and cash equivalents, enough to fund its operations into early 2028.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is an American clinical-stage biotechnology company based in Salt Lake City, Utah. The company uses a combination of artificial intelligence, machine learning, and other advanced systems to accelerate drug discovery and development.

While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: David Abrams’ Hedge Fund Is Betting On These 8 Stocks and 10 Best Energy Storage Stocks to Buy According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.